Scarica l'app Stockscreener
4.65
10.49%
-0.545
Dopo l'orario di chiusura:
4.70
0.05
+1.08%
Precedente Chiudi:
$5.195
Aprire:
$5.12
Volume 24 ore:
2.60M
Relative Volume:
2.44
Capitalizzazione di mercato:
$279.76M
Reddito:
-
Utile/perdita netta:
$-44.80M
Rapporto P/E:
-6.20
EPS:
-0.75
Flusso di cassa netto:
$-30.67M
1 W Prestazione:
-15.45%
1M Prestazione:
-8.64%
6M Prestazione:
-16.37%
1 anno Prestazione:
-24.39%
Intervallo 1D:
$4.365
$5.12
Intervallo di 1 settimana:
$4.365
$5.74
Portata 52W:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Nome
Aldeyra Therapeutics Inc
Settore
Industria
Telefono
781-761-4904
Indirizzo
131 HARTWELL AVENUE, LEXINGTON, MA
Compare ALDX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
4.65 | 312.55M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-04-27 | Ripresa | H.C. Wainwright | Buy |
| 2021-02-08 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-10-30 | Iniziato | Jefferies | Buy |
| 2020-10-16 | Iniziato | BTIG Research | Buy |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Outperform |
| 2018-12-04 | Iniziato | Citigroup | Buy |
| 2018-09-26 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Iniziato | Janney | Buy |
| 2018-01-26 | Iniziato | Seaport Global Securities | Buy |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-01 | Iniziato | Stifel | Buy |
| 2015-07-01 | Iniziato | Canaccord Genuity | Buy |
| 2015-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2015-03-20 | Reiterato | H.C. Wainwright | Buy |
| 2014-11-18 | Iniziato | H.C. Wainwright | Buy |
| 2014-06-19 | Iniziato | Aegis Capital | Buy |
Mostra tutto
Aldeyra Therapeutics Inc Borsa (ALDX) Ultime notizie
HC Wainwright Issues Pessimistic Estimate for ALDX Earnings - MarketBeat
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Below 200-Day Moving AverageHere's What Happened - MarketBeat
How volatile is Aldeyra Therapeutics Inc. stock2025 Technical Overview & Community Verified Watchlist Alerts - mfd.ru
EBITDA per share of Aldeyra Therapeutics, Inc. – DUS:137 - TradingView
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ: ALDX) outlines reproxalap, ADX-2191 and AbbVie deal - Stock Titan
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Published on: 2026-02-28 16:42:08 - baoquankhu1.vn
Coya Therapeutics, Inc. (COYA) upgraded to buy: What does it mean for the stock? - MSN
Aldeyra Therapeutics, Inc.Common Stock (NQ: ALDX - The Chronicle-Journal
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference - MarketBeat
Overview of FDA Regulatory Developments - Intellectia AI
Aldeyra Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Friday - MarketBeat
Understanding Momentum Shifts in (ALDX) - Stock Traders Daily
Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect? - Zacks Investment Research
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - marketscreener.com
Biotech CEO in fireside chat at Oppenheimer health conference - Stock Titan
Perceptive fund discloses 7% Aldeyra (ALDX) ownership stake - Stock Titan
Biotech Stocks Facing FDA Decision In March 2026 - RTTNews
Does Aldeyra Therapeutics Inc. have a sustainable dividendJuly 2025 Reactions & Daily Profit Maximizing Tips - mfd.ru
Aldeyra's Dry Eye Therapy Faces FDA In MarchWill The Third Time Be A Charm? - RTTNews
Published on: 2026-02-12 20:14:42 - baoquankhu1.vn
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Avoiding Lag: Real-Time Signals in (ALDX) Movement - Stock Traders Daily
Wall Street analysts predict a 65.75% upside in Aldeyra Therapeutics (ALDX): Here's what you should know - MSN
Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's What You Should Know - Finviz
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN
Are Medical Stocks Lagging Aldeyra Therapeutics (ALDX) This Year? - Yahoo Finance
Aldeyra’s Dry Eye Drug Faces A Make-Or-Break FDA Call - Finimize
PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Discipline and Rules-Based Execution in ALDX Response - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Earnings Recap: Is Aldeyra Therapeutics Inc exposed to political riskQuarterly Risk Review & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Market Review: Does Aldeyra Therapeutics Inc have consistent dividend growthJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Will BOOT benefit from green energy policies2025 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewir - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Thera - The National Law Review
ATA Creativity Global Among 3 Promising Penny Stocks - Yahoo Finance
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update - MarketBeat
Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily
FDA Extends Review Timeline for Aldeyra's Dry Eye Drug Candidate () - aktiencheck.de
Support Test: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus
Head to Head Review: Scienture (NASDAQ:SCNX) & Aldeyra Therapeutics (NASDAQ:ALDX) - Defense World
Analysis Recap: Is Aldeyra Therapeutics Inc stock trending bullish2025 Momentum Check & Community Trade Idea Sharing Platform - baoquankhu1.vn
Insider Buy: Does National Energy Services Reunited Corp Equity Warrant stock reflect fundamentals2025 Market Overview & Risk Controlled Swing Alerts - baoquankhu1.vn
Trend Review: Is Envirotech Vehicles Inc in accumulation or distribution phaseJobs Report & Consistent Profit Trade Alerts - baoquankhu1.vn
Aldeyra Therapeutics Inc Azioni (ALDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):